Axsome Therapeutics ( (AXSM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Axsome Therapeutics shares gained after the company posted strong preliminary revenue numbers for the fourth quarter and full-year 2025, with sales rising about 65–66% from a year earlier. The jump was driven mainly by its depression drug AUVELITY, while SUNOSI held steady and the newly launched SYMBRAVO started to contribute early revenue. Analysts highlighted the accelerating commercial momentum, a positive tone on the earnings call, and progress in the company’s drug pipeline and regulatory path as key reasons behind the improved outlook and recent upward revisions to their valuation views and price targets. However, they also cautioned that ongoing losses, negative cash flow, a heavy debt load, and the preliminary nature of the figures still limit how far the stock’s valuation can run in the near term.
More about Axsome Therapeutics
YTD Price Performance: -8.26%
Average Trading Volume: 601,480
Technical Sentiment Signal: Buy
Current Market Cap: $8.45B
For further insights into AXSM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.